Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma plus treatment of physician’s choice in HER2-positive metastatic breast cancer after ≥2 HER2-directed regimens
KCT0003425Phase 2Completed
- Sponsor
- Ministry of Health & Welfare
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Ministry of Health & Welfare. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on KCT0003425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003425.